11 Dec 21 | Samsung Bioepis announced that SB12 (proposed eculizumab biosimilar) met all the endpoints in a Ph I study. 13 Dec 21 | Xbrane Biopharma announced it is developing...
Pearce IP BioBlast® w/e 17 December 2021
read more
PTE Alert – interlocutory injunction refused in Tecfidera® dispute
In early November Pearce IP reported on a number of Federal Court decisions which appear to indicate flaws in the Australian Patent Office’s interpretation of the eligibility...
Vague proposals do not an inventor make
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP BioBlast® w/e 10 December 2021
06 Dec 21 | AU | Australia’s TGA provisionally approved Celltrion’s Regkirona® (regdanvimab) for the treatment of adults with coronavirus who do not require supplemental oxygen...
Full Court finds another computer-implemented scheme unpatentable
Repipe Pty Ltd v Commissioner of Patents (No 3) [2021] FCA 31: Repipe Pty Ltd v Commissioner of Patents [2021] FCAFC 223
Date: 29 January 2021 Court: Federal Court of Australia Judge: McKerracher J Date: 08 December 2021 Court: Full Court of the Federal Court of Australia Judges: Perram, Nicholas...
Vague proposals do not an inventor make
Vehicle Monitoring Systems Pty Ltd v SARB Management Group Pty Ltd [2021] FCAFC 224
Date: 08 December 2021Court: Full Court of the Federal Court of AustraliaJudges: Nicholas, Yates and O'Bryan JJ Background Australian Patent Application 2013213708 (708...
Pearce IP BioBlast® w/e 03 December 2021
01 Dec 21 | CN | Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the treatment of patients with advanced, metastatic or recurrent...
Pearce IP is Intellectual Property Team of the Year
Australian Law Awards (Lawyers Weekly)
It is our great privilege to share that Pearce IP was honoured as “Intellectual Property Team of the Year” at the Lawyers Weekly Australian Law Awards (2021) on 2nd December. ...
Pearce IP BioBlast® w/e 26 November 2021
21 Nov 21 | CN | Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in patients with EGFR-mutated...
Breaking News – Parliament delivers early Christmas present for Health Care
In the last sitting of Parliament for 2021, the House of Representatives delivered the long-awaited Zimmerman Report, more formally entitled “The new frontier—delivering better...
Naomi Pearce is Lawyers Weekly WIL Partner of the Year 2021
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, was awarded the title of 2021 Partner of the Year...
Disclaimer amendment allowed in mastitis patent
Boehringer Ingelheim Animal Health USA Inc v Elanco New Zealand [2021] FCA 1457
Date: 25 November 2021Court: Federal Court of AustraliaJudge: Besanko J Background This appeal from a decision of the Australian Patent Office concerned the allowability of...
Pearce IP BioBlast®: w/e 19 November 2021
15 Nov 21 | EU | Celltrion announced that the EC has approved Regkirona® (regdanvimab, CT-P59) for adults with COVID-19 who do not require supplemental oxygen and who are at...
No jackpot for Aristocrat as Full Court finds electronic gaming machine claim unpatentable
Commissioner of Patents v Artistocrat Technologies Australia Pty Ltd (2021) FCAFC 202
Date: 19 November 2021Court: Full Court of the Federal Court of AustraliaJudges: Middleton, Perram and Nicholas JJ Background In 2018 the Australian Patent Office refused to...
Pfizer quest for Samsung Bioepsis etanercept documents continues
Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 3) [2021] FCA 1428
Date: 18 November 2021Court: Federal Court of AustraliaJudge: Burley J Background In December 2016 Pfizer Ireland Pharmaceuticals (Pfizer) filed a preliminary discovery...
Hold onto your Hats! – Expedited Patent Litigation in Australia
The speed of getting a case to trial is a key metric of any litigation system. Pharmaceutical patent litigation often plays out on the cusp of patent expiry when a new market...
Pearce IP BioBlast®: w/e 12 November 2021
09 Nov 21 | Coherus BioSciences reported its Q3 2021 financial results. Coherus announced that FDA review of CHS-201 (proposed adalimumab biosimilar) is advancing towards the...
Pearce IP BioBlast®: w/e 05 November 2021
01 Nov 21 | The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its second Global Biosimilars Week to join the Biosimilars Movement...
PTE Alert: Recent cases create fertile ground for PTE challenges
In the last year, two significant Federal Court decisions, reported here and here have exposed key flaws in the Australian Patent Office’s interpretation of the eligibility...
Pearce IP BioBlast®: w/e 29 October 2021
22 Oct 21 | Biocon released its Q2 2022 financial results, reporting a 10% increase in biosimilars revenue year on year. 22 Oct 21 | Chugai Pharmaceutical announced that it will...
Pearce IP BioBlast®: w/e 22 October 2021
14 Oct 21 | Gan & Lee Pharmaceuticals announced the completion of two Ph III studies of its proposed insulin glargine biosimilar. 15 Oct 21 | US | Roche announced that the...
Strategies for generic/biosimilar market entry in Australia
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second...
Is best practice for patent validity in Australia an impossible task?
The evolution of jurisprudence in Australia can have far reaching implications for legal practitioners in every jurisdiction. Two recent Federal Court decisions have given...
Pearce IP BioBlast®: w/e 15 October 2021
05 Oct 21 | EU | Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of COVID-19 in...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.